Compare
Delcath Systems, Inc. vs Iradimed Corp vs Pulmonx Corp vs PRO DEX Inc
| Latest fiscal year | Delcath Systems, Inc. DCTH | Iradimed Corp IRMD | Pulmonx Corp LUNG | PRO DEX Inc PDEX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $85.23M | $83.81M | $90.50M | $77.55M |
| Revenue growth (YoY) | +129.1% | +14.4% | +8.0% | +16.5% |
| Gross margin | 86.2% | 76.7% | 74.2% | 31.4% |
| Operating margin | 0.8% | 31.2% | -59.3% | 16.8% |
| Net margin | 3.2% | 26.8% | -59.7% | 17.6% |
| Net income | $2.70M | $22.48M | -$54.00M | $13.66M |
| EPS (Diluted) | $0.07 | $1.75 | -$1.33 | $4.12 |
| Operating cash flow | $22.52M | $24.95M | -$32.38M | $7.24M |
| Free cash flow | $20.97M | $17.18M | -$32.83M | $6.76M |
| Cash & equivalents | $43.45M | $51.16M | $69.75M | $8.19M |
| Total assets | $123.63M | $108.78M | $129.29M | $74.51M |
| Total liabilities | $12.41M | $14.16M | $75.17M | $26.88M |
| Shareholders' equity | $111.22M | $94.62M | $54.12M | $47.63M |
| Return on year-end equity | 2.4% | 23.8% | -99.8% | 28.7% |
| Shares outstanding | 34.69M | 12.78M | 41.67M | 3.19M |
Revenue, most recent five fiscal years
| Fiscal year | Delcath Systems, Inc. | Iradimed Corp | Pulmonx Corp | PRO DEX Inc |
|---|---|---|---|---|
| Latest | $85.23M Ended 2025-12-31 | $83.81M Ended 2025-12-31 | $90.50M Ended 2025-12-31 | $77.55M Ended 2026-06-30 |
| 1 year earlier | $37.20M Ended 2024-12-31 | $73.24M Ended 2024-12-31 | $83.79M Ended 2024-12-31 | $66.59M Ended 2025-06-30 |
| 2 years earlier | $2.06M Ended 2023-12-31 | $65.56M Ended 2023-12-31 | $68.67M Ended 2023-12-31 | $53.84M Ended 2024-06-30 |
| 3 years earlier | $2.72M Ended 2022-12-31 | $53.30M Ended 2022-12-31 | $53.66M Ended 2022-12-31 | $46.09M Ended 2023-06-30 |
| 4 years earlier | $3.56M Ended 2021-12-31 | $41.81M Ended 2021-12-31 | $48.42M Ended 2021-12-31 | $42.04M Ended 2022-06-30 |